EXTENSIVE STAGE SMALL CELL LUNG CANCER

This study is testing a new drug called tarlatamab, given alongside standard chemotherapy and an immunotherapy drug, for people newly diagnosed with extensive stage small cell lung cancer. The main goal is to see if this combination is safe and tolerable for patients. Researchers…

This study is testing whether a personalized vaccine, designed from a patient's own tumor, can help the immune system fight cancer when given alongside an immunotherapy drug (durvalumab). It aims to see if this combination is safe, feasible to make, and can help control the disea…

This study is for people with extensive-stage small-cell lung cancer who have already completed their first round of chemotherapy and immunotherapy (durvalumab) without their cancer getting worse. It aims to see if adding a new drug called tarlatamab to their ongoing durvalumab t…

This study is testing a new targeted drug called ifinatamab deruxtecan for people with extensive-stage small cell lung cancer that has worsened after previous treatments. The trial aims to find the best dose and see how well the drug shrinks tumors and controls the cancer. About …

This study is testing an investigational drug called tarlatamab for Chinese adults with advanced small cell lung cancer that has continued to grow after at least two prior treatments. The main goal is to see if the drug can shrink tumors and control the cancer. Researchers will a…

This study is testing whether adding a new radioactive drug called [177Lu]Lu-DOTA-TATE to standard chemotherapy and immunotherapy can better control an aggressive type of lung cancer. It aims to find a safe dose and see if this combination helps patients live longer compared to s…

This study is testing a new drug called BNT327, given alongside standard chemotherapy, for people with a fast-growing type of lung cancer called small-cell lung cancer. It is for two groups: people who have not yet received treatment for their advanced cancer, and people whose ca…

This study is testing whether adding two immunotherapy drugs (monalizumab and durvalumab) to standard chemotherapy helps people with small cell lung cancer live longer without their cancer getting worse. It includes two groups: people with newly diagnosed advanced cancer and peop…

This study is testing if adding a short, precise course of radiation (SBRT) to standard immunotherapy and chemotherapy is safe for people with extensive-stage small cell lung cancer. It focuses on patients whose cancer does not shrink enough after the first two cycles of standard…

This study compares two different immunotherapy drugs (serplulimab and atezolizumab) when combined with standard chemotherapy for people with advanced small cell lung cancer who haven't had previous treatment. Researchers want to see which drug combination helps patients live lon…

This study is testing whether adding an experimental drug called BMS-986012 to standard chemotherapy and immunotherapy works better for people newly diagnosed with extensive-stage small cell lung cancer. Researchers want to see if this combination is safe and can help patients li…